P1101 had durable hematologic responses and manageable safety among patients with essential thrombocythemia, meeting the ...
With phase 3 trial win, PharmaEssentia plots label expansion for rare blood cancer treatment Besremi
PharmaEssentia is looking to expand the reach of its FDA-approved rare blood cancer treatment Besremi to another rare blood ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback